Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors | Zendy

Daniel Cho | Zendy

Open Access

Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors

Author(s) -

Daniel Cho

Publication year - 2013

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s45872

Subject(s) - renal cell carcinoma , medicine , biomarker , tyrosine kinase , vegf receptors , vascular endothelial growth factor , tyrosine kinase inhibitor , receptor tyrosine kinase , clear cell renal cell carcinoma , biomarker discovery , oncology , cancer research , cancer , bioinformatics , receptor , proteomics , biology , biochemistry , gene

Tyrosine kinase inhibitors with activity against vascular endothelial growth factor receptor 2 are now standard treatment for the majority of patients with advanced renal cell carcinoma. The clinical development of these agents followed by their broad clinical utilization has allowed the creation of large databases to facilitate the identification of prognostic biomarkers and development of prognostic models. While several clinical prognostic models have been created, work continues on identifying novel biomarkers which might be used in conjunction with or even in place of these clinical models. In this review, we discuss the progress thus far in improving on current prognostic models and speculate on possible developments in the near future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research